Physician profile
Abdel Jibawi
NPI 1912261876
$3,505.25
in general payments reported to CMS, 2019-2025
27 companies · $571 in 2025
The $571 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $251 · 2021: $53.01 · 2022: $314 · 2023: $902 · 2024: $863 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,335.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $915.17 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $505.53 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.54 | 2019-2025 | Spiriva Respimat, Jardiance |
| Pfizer INC. | $289.81 | 2019-2025 | |
| Amgen INC. | $256.11 | 2022-2025 | Repatha, Repatha, Otezla |
| Astellas Pharma US INC | $242.85 | 2019-2023 | Veozah |
| Comsort, INC | $150.00 | 2019 | |
| Medtronic Vascular, INC. | $113.58 | 2019 | |
| Abbvie INC. | $110.36 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $85.23 | 2023-2024 | Dificid, Delstrigo, Pifeltro |
| Janssen Pharmaceuticals, INC | $72.44 | 2019-2020 | |
| Lilly USA, LLC | $55.62 | 2019-2024 | Mounjaro |
| Inari Medical, INC. | $50.91 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Scilex Pharmaceuticals INC. | $48.12 | 2024 | |
| Novartis Pharmaceuticals Corporation | $37.43 | 2022-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $36.92 | 2019-2022 | |
| Bioventus LLC | $33.12 | 2024 | Supartz Fx Sodium Hyaluronate |
| Nevro Corp. | $32.49 | 2023 | Senza |
| Dexcom, INC. | $24.32 | 2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.19 | 2019 | |
| Exact Sciences Corporation | $20.00 | 2025 | The Cologuard Plus Collection Kit |
| Alnylam Pharmaceuticals INC. | $19.50 | 2024 | Givlaari |
| Allergan, INC. | $19.01 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.54 | 2024 | |
| Celgene Corporation | $18.14 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.87 | 2024 | Eliquis |
| Amarin Pharma, INC. | $13.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdel Jibawi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.